Medicare Covering Epic Sciences ctDNA Breast Cancer Panel, MDxHealth’s Select MDx Test

Epic Sciences said on Wednesday that its 56-gene circulating tumor DNA (ctDNA) panel for genomic profiling of metastatic breast cancer has received a positive Medicare coverage decision from Palmetto GBA, a Medicare administrative contractor through the Molecular Diagnostics Services (MolDX) program.

Separately, MDxHealth said that the technical assessment process with MolDX for its Select MDx test has been successfully completed, and the test will be reimbursed by Medicare. MDxHealth acquired the Oncotype DX Genomic Prostate Score from Exact Sciences last year.

Epic’s test is covered under a foundational LCD for Plasma-Based Genomic Profiling in Solid Tumors, while MDxHealth’s test is covered under a foundational LCD for Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer.

Source: https://www.genomeweb.com/liquid-biopsy/medicare-covering-epic-sciences-ctdna-breast-cancer-panel-mdxhealths-select-mdx-test#.ZELXSXbMKUk